))
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
Manage episode 153141027 series 1082357
Content provided by cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
307 episodes
Share
